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The transcellular trafficking of iron from the blood into the brain interstitium depends on
iron uptake proteins in the apical membrane of brain microvascular capillary endothelial
cells and efflux proteins at the basolateral, abluminal membrane. In this review, we
discuss the three mechanisms by which these cells take-up iron from the blood and
the sole mechanism by which they efflux this iron into the abluminal space. We then
focus on the regulation of this efflux pathway by exocrine factors that are released
from neighboring astrocytes. Also discussed are the cytokines secreted by capillary cells
that regulate the expression of these glial cell signals. Among the interstitial factors that
regulate iron efflux into the brain is the Amyloid precursor protein (APP). The role of this
amyliodogenic species in brain iron metabolism is discussed. Last, we speculate on the
potential relationship between iron transport at the blood-brain barrier and neurological
disorders associated with iron mismanagement.
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Introduction
Organismal iron is a co-factor utilized for several specific enzymatic processes and, in higher
eukaryotes, iron is essential for hemoglobin, myoglobin, neurotransmitter synthesis, myelination
of neurons, and energy-producing redox reactions (Beard, 2003; Levi and Rovida, 2009; Todorich
et al., 2009; Horowitz and Greenamyre, 2010; Chen and Paw, 2012). Therefore the brain, which is
the most metabolically active organ in the body, has a high demand for iron and actively engages
in maintaining appropriate amounts of the element within its confines. Brain iron maintenance
is complex and involves both diurnal and regional regulation (Unger et al., 2009, 2014). The
brain utilizes a detailed regulatory network involving cell-to-cell signaling and acute phase iron-
regulatory proteins to transport iron from the blood, across the blood-brain barrier (BBB), and into
the brain. However, before iron can enter the brain through the BBB it must first be acquired from
the diet through a separate barrier system: the duodenal enterocyte barrier. Mechanisms of iron
transport and regulation have been widely studied in the duodenal enterocytes and have been used
as the foundation for studies examining the iron regulatory mechanisms at the BBB.
Systemic Iron Uptake and Transport
At the duodenal enterocyte barrier, lumenal ferric iron (Fe3+) is reduced to ferrous iron (Fe2+) at
the brush border (lumenal surface) of the duodenal enterocyte by an endogenous ferrireductase
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known as duodenal cytochrome b (Dcytb; McKie et al., 2001).
Dcytb functions by transporting an electron from an endogenous
cytosolic reductant, such as Nicotinamide adenine dinucleotide
phosphate (NAD(P)H), to extracellular Fe3+. After reduction,
Fe2+ crosses the lumenal surface of the duodenal enterocyte
through divalent metal transporter 1 (DMT1; Fleming et al.,
1999; Canonne-Hergaux et al., 2000; Oates et al., 2000). This
function for DMT1 was indicated by phenotypic characterization
of the Belgrade rat which contains a missense mutation in the
Nramp2 gene (encoding DMT1) and is impaired for intestinal
iron absorption (Fleming et al., 1998). Once inside the enterocyte,
iron can be utilized for assembly of Fe/S clusters and maturation
of cytochromes and various non-heme iron enzymes;, stored in
the iron storage protein ferritin; or exported out of the cell at the
abluminal surface (blood-side).
Iron export from the abluminal surface of the duodenal
enterocyte occurs via transport through the only known
mammalian iron export protein, ferroportin (Fpn; Abboud and
Haile, 2000; Donovan et al., 2000, 2005; McKie et al., 2000;
Ganz, 2005; Han and Kim, 2007). The export of iron from
Fpn (IREG1/SLC40A1/MTP1) requires the oxidation of that iron
by an exocytoplasmic ferroxidase. Tethered to the extracellular
surface of the duodenal enterocyte abluminal membrane is the
multi-copper ferroxidase hephaestin (Hp; Vulpe et al., 1999;
Anderson et al., 2002a; Han and Kim, 2007). Hp catalyzes
the oxidation of Fe2+ to Fe3+ allowing for export of that
iron from Fpn and its subsequent association with the iron-
binding glycoprotein transferrin (Tf). A block in intestinal iron
transport (specifically, a block in the efflux of iron from the
enterocytes) was observed in the sex-linked anemia (sla) mouse
(Hephsla/Hephsla), which expresses a truncated form of Hp
(Vulpe et al., 1999).
Now in the blood and bound to Tf, iron is transported
safely throughout the bloodstream to be utilized by cells
expressing the Tf receptor (TfR) on their surface. As high levels
of iron accumulate in the serum, Tf becomes saturated and
the increased levels of the diferric-Tf (holo-Tf) complex are
sensed by liver hepatocytes. When iron replete, hepatocytes
synthesize and secrete the peptide hormone hepcidin into
serum (Anderson et al., 2002b; Lin et al., 2007; Anderson and
Vulpe, 2009). The hepcidin peptide will enter the circulation
and bind to its receptor Fpn; this interaction induces the
internalization and subsequent lysosomal degradation of both
Fpn and hepcidin (Nemeth et al., 2004; Ganz and Nemeth,
2012). Regulation of duodenal Fpn occurs post-translationally
via this mechanism of hepcidin internalization. In addition,
the major Fpn transcript contains an iron-responsive element
(IRE) that is regulated by a set of iron-regulatory proteins (IRP1
and IRP2); these proteins bind to the IRE in response to low
intracellular iron levels and prevent translational initiation of
the transcript (Casey et al., 1988; Leipuviene and Theil, 2007).
With fewer Fpn-expressing duodenal enterocytes, iron entry
into the blood is diminished. However, duodenal enterocytes
express also a 1b-isoform of Fpn which lacks an IRE in its
5′ untranslated region (UTR); thus, unlike many other iron
handling gene products, the Fpn expression from this transcript
bypasses the normal IRP-dependent repression of intestinal
iron uptake (Zhang et al., 2009). This description defines the
main regulatory axis for iron entry into the systemic circulation
through the abluminal surface of the duodenal enterocyte
barrier.
Iron Mobilization from Blood to Brain:
Mechanisms of Transport Across the BBB
Similar to the duodenal enterocyte barrier, iron entry into
the brain is regulated at the BBB by a regulatory network
involving multiple cell types and signaling molecules. The BBB
is a barrier system coordinated by three different cell types:
brain microvascular endothelial cells (BMVEC), astrocytes, and
pericytes (Abbott et al., 2006). The pericytes of the BBB
are thought to be involved in vaso-constriction and dilation
of the blood vessel and will not be discussed further in
this review. Here we will focus on the regulation of iron
transport from the blood, through the BBB, and into the
brain with the view that the BMVEC and astrocytes form a
regulatory axis which modulates this process. We note the
similarities between systemic iron regulation at the duodenal
enterocyte barrier and what is known about the central nervous
system’s (CNS) iron regulatory mechanisms as they pertain
to the BBB.
The BMVEC of the BBB are a polarized cell type
exposed to two distinct environments on their opposing
apical and basal surfaces (Figure 1). The BMVEC are
exposed to circulating holo-Tf (TBI) and non-Tf bound
iron (NTBI) species at their apical (blood) surface. BMVEC
express approximately 100,000 Tf receptors per cell on their
plasma membrane and readily accumulate iron from holo-
Tf via a canonical Tf-TfR mediated uptake pathway as
evidenced by in vitro examination of hBMVEC Tf-iron uptake
(Raub and Newton, 1991; McCarthy and Kosman, 2012,
2013).
Canonical Tf-iron uptake by BMVEC begins when holo-
Tf binds to the TfR [affinity is ∼1022 M−1 at pH 7.4 (Aisen
et al., 1978)] on the apical surface of BMVEC resulting in
a clathrin-dependent endocytosis of the Tf-TfR complex and
the subsequent formation of an early endosome. Within the
endosome iron will be reduced and released from Tf and
will subsequently exit the endosome through a divalent cation
transporter such as DMT1 (Figure 1; Fleming et al., 1998; Burdo
et al., 2001; McCarthy and Kosman, 2012). For iron to be released
from Tf in the endosome the electrochemical potential (E◦)
of the complex (<−500 mV Kraiter et al., 1998) needs to be
made more positive than that of the endogenous reductants.
The E◦ of the Tf-iron complex will be made more positive
and iron will be effectively released from Tf in the endosome
as a result of: (1) Tf binding to the TfR; (2) a reduction in
endosomal pH; and (3) the presence of exogenous ligand (e.g.,
citrate; Byrne et al., 2010; Steere et al., 2010). The drop in
endosomal pH [from 7.4 to 5.6 (Byrne et al., 2010)] occurs
via the action of an endosomal H+-ATPase pumping protons
into the endosome (Nelson and Harvey, 1999). The subsequent
reduction of Fe3+ from Tf within the endosome occurs via
the transfer of an electron from a cytosolic reductant such as
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FIGURE 1 | Iron trafficking mechanisms across a brain microvascular
endothelial cell. Mechanism(s) of iron trafficking depicted include transferrin
iron uptake (TBI uptake) and non-transferrin bound iron uptake (NTBI uptake).
Whether accumulating in the cytosol as a result of release from the endosome,
or as a result of transport across the apical membrane via a divalent metal ion
transporter, the Fe2+ can efflux from the capillary cell back into the blood, or at
the basal membrane into the brain interstitium. This efflux is via the ferrous iron
transporter, ferroportin (Fpn); iron release from Fpn into the extracellular milieu
depends on the ferrous iron oxidation activity (ferroxidase activity) by a
multi-copper oxidase, either ceruloplasmin (Cp) or hephaestin (Hp).
NAD(P)H through an endosomal ferrireductase, and to the iron
(Ohgami et al., 2005). Reductases identified in BMVEC include
duodenal cytochrome b (Dcytb) and the six transmembrane
epithelial antigen of the prostate 2 (Steap2; McCarthy and
Kosman, 2012).
After the reduction of iron from Tf within the cycling
endosome, the Fe2+ is then exported out of the endosome
through a divalent cation transporter. DMT1 is the only divalent
cation transporter to have been identified in BMVEC to date and
has been localized with TfR in cycling endosomes within BMVEC
(Burdo et al., 2001; Siddappa et al., 2002; McCarthy and Kosman,
2012; Du et al., 2014; Simpson et al., 2015); however, controversy
concerning the expression and functional significance of DMT1
in BMVEC still remains (Moos et al., 2006; Skjørringe et al.,
2012).
As an alternative to TBI uptake by BMVEC, NTBI uptake
can occur at the apical surface of BMVEC (McCarthy and
Kosman, 2012). NTBI in the blood may be bound to a variety
of ligands (e.g., citrate, ATP, and albumin). When in spatial
proximity to the apical surface of BMVEC, NTBI may be reduced
to Fe2+ by a cell surface ferrireductase (Figure 1; McCarthy
and Kosman, 2012). This ferrireduction has been suggested
by the localization of non-heme ferrous iron at the apical
surface of rat BMVEC (Meguro et al., 2008). Furthermore, we
have demonstrated the cell-surface reduction of both TBI and
NTBI in vitro using human BMVEC (hBMVEC) in combination
with the colorimetric indicator ferrozine which reacts with
the reduced Fe2+ to form a pink complex (McCarthy and
Kosman, 2012). The ferrireductases which are functionally
relevant to the reduction of iron at the BMVEC cell surface
are unknown. As with the canonical Tf-TfR endosomal cycling
pathway, cell-surface reduced Fe2+ can enter the cell through
a divalent cation transporter (e.g., DMT1, Zip8, and Zip14).
However, expression of Zip8 and Zip14 in BMVEC has not been
examined.
Once ferrous iron enters the apical surface of the BMVEC
through DMT1 it needs to be distributed throughout the cell
and, relevant to this review, to the basal membrane of the cell
to be exported into the brain. Upon import through DMT1,
Fe2+ may be transferred to the DMT1-binding protein poly(rC)-
binding protein 2 (PCBP2) which acts as a chaperone to
deliver iron to iron-requiring enzymes, ferritin, and possibly
even Fpn with which PCBP2 has been shown to interact (Shi
et al., 2008; Leidgens et al., 2013; Frey et al., 2014; Lane
and Richardson, 2014; Philpott and Ryu, 2014; Yanatori et al.,
2014). The details of iron transport within the cytosol of the
BMVEC have not been thoroughly investigated and the role
of iron chaperones such as PCBP2 in this cell type remains
unclear.
Irrespective of the chaperones involved, cytosolic iron will
eventually be transferred to Fpn for export from the cell. Fpn
is expressed by BMVEC and is localized to both their apical
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and basolateral surfaces (Wu et al., 2004; Enerson and Drewes,
2005; Yang et al., 2011; McCarthy and Kosman, 2013, 2014b;
McCarthy et al., 2014; Simpson et al., 2015). This distribution
of Fpn suggests iron may be returned to the circulation through
Fpn localized on the apical surface of BMVEC; alternatively,
iron can traffic into the brain through Fpn localized to the
basolateral surface of these cells (Figure 1; McCarthy and
Kosman, 2013, 2014b). Fpn is essential for brain development
as Fpn knockout in mice is embryonic lethal while the Fpn
trafficking mutant, flatiron (ffe/ffe), results in neural tube and
forebrain development defects. Both phenotypes are due in part
to the iron deficiency created by the lack of Fpn trafficking to
the plasma membrane of cells (Donovan et al., 2005; Mao et al.,
2010).
Similar to the duodenal enterocyte, iron efflux from BMVEC
Fpn requires the action of an exocytoplasmic ferroxidase
(Figure 2). In the case of hBMVEC, this ferroxidase activity
may be provided by endogenous Hp or, when co-cultured
with astrocytes, astrocyte-secreted soluble ceruloplasmin (sCp;
McCarthy and Kosman, 2013, 2014b); expression of Hp by
various cell types and tissues of the brain including BMVEC has
been demonstrated (Qian et al., 2007; Wang et al., 2007; Cui
et al., 2009; Yang et al., 2011). In culture, Hp is localized to the
basolateral surface of hBMVEC where it likely acts in concert
with basolateral Fpn to efflux iron from the cells (McCarthy and
Kosman, 2013). Hp has been shown to enhance iron efflux from
other cells of the CNS, i.e., oligodendrocytes. Oligodendrocytes
cultured from sla mice (as noted, carrying a mutation in the
FIGURE 2 | Iron efflux from brain microcapillary endothelial cells
depends on ferroxidase activity. The ferroxidases, Hp and Cp, appear to
support Fpn iron-efflux via two mechanisms which may not be separable: (1)
in the presence of either active enzyme, the surface of expression of cellular
Fpn increases, i.e., there are more Fpn transporters in the plasma membrane;
and (2) the ferroxidase activity provided is proposed to “catalyze” the
trafficking of Fe2+ through Fpn. This diagram illustrates that in the abluminal
space of the BBB, in addition to Hp expressed by the BMVEC, sCp secreted
by neighboring astrocytes plays a substantial role in supporting efflux of iron
through the Fpn at the abluminal surface of BMVEC (McCarthy and Kosman,
2014b).
hephaestin gene; Vulpe et al., 1999) are significantly deficient
in their ability to efflux 55Fe in comparison to oligodendrocytes
cultured from their wild type littermates (Schulz et al., 2011). The
extent to which BMVECHp plays a role in glial cell iron handling
in the adult rodent remains to be seen as the expression of Hp
by these cells appears to be depleted in adulthood (Yang et al.,
2011).
In sla mice, the Hp expressed exhibits reduced ferroxidase
activity suggesting a compensatory mechanism enabling them
to retain their ability to transport iron into the brain. Indeed,
Cp has been shown to fulfil this role for Hp depletion in the
white matter of the CNS from slamice (Schulz et al., 2011). This
compensatory ferroxidase activity can be provided by astrocyte-
secreted sCp. The effect of astrocyte sCp on hBMVEC iron
efflux has been thoroughly demonstrated in vitro using a three
dimensional reconstruction of the BBB (McCarthy and Kosman,
2014b). Stimulation of iron efflux from hBMVEC by astrocyte-
conditionedmedia was abrogated upon immunodepletion of sCp
from that media (McCarthy and Kosman, 2014b). Therefore, it
is likely that sCp from astrocytes provide adequate ferroxidase
activity to stimulate the efflux of iron from Fpn at the basolateral
surface of BMVEC. It should be noted however that Hp/Cp
double-mutant mice still accumulate iron in the CNS suggesting
further, yet undefined, compensatory mechanisms (Hahn et al.,
2004; Hadziahmetovic et al., 2008; Schulz et al., 2011). Recently,
Simpson et al demonstrated that iron efflux from rat BMVEC
is enhanced by apo-Tf (Simpson et al., 2015). Whether or
not apo-Tf compensates for BMVEC iron efflux in the Hp/Cp
double-mutant mice is unclear. Perhaps a newly discovered
ferroxidase, Zyklopen (Zp), fulfills this role (Danzeisen et al.,
2002; Chen et al., 2010). Further examination of this hypothesis
is required.
Hepcidin Regulation of Iron Transport
Across the BBB
Iron release from the abluminal surface of the duodenal
enterocyte is regulated by the surface expression of Fpn. Fpn
surface expression is differentially regulated by a balance of
ferroxidase activity (e.g., Hp and/or sCp) and the peptide
hormone hepcidin which is secreted by the liver in response
to high levels of circulating holo-Tf. The basolateral surface of
the BMVEC of the BBB is closed off from the circulation and
therefore may not respond to circulating levels of sCp and/or
hepcidin. Due to the lack of sCp/hepcidin permeability across
the BBB and the high probability that the liver does not respond
to brain iron levels, there must be a centralized system within
the CNS responsible for regulating brain iron uptake through the
BMVEC.
In keeping with the lessons learned from duodenal
enterocyte Fpn regulation, several groups have examined
the regulation of BMVEC Fpn by hepcidin. Hepcidin mRNA
has been demonstrated to be widely expressed in mouse
brain; furthermore, injection of hepcidin into the ventricles
of the mouse brain induced a rapid depletion of overall brain
Fpn suggesting hepcidin may indeed play a role in brain
iron metabolism (Wang et al., 2010). Hadziahmetovic et al.
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demonstrated increased Fpn expression in the BMVEC of
hepcidin null mouse mutants (Hadziahmetovic et al., 2011);
this apparent effect of hepcidin on BMVEC Fpn has been
corroborated (Du et al., 2014). Addition of hepcidin to cultured
primary BMVEC reduces the expression of not only Fpn but
also TfR and DMT1 suggesting that TfR and DMT1 transcripts
are responding to elevated iron within the cell caused by Fpn
depletion (i.e., decreased iron efflux; Du et al., 2014; Simpson
et al., 2015).
While these data would indicate that hepcidin may be
directly involved in BMVEC Fpn regulation, the cell type(s)
from which the hepcidin peptide is generated within the
brain has been examined. In 2014, we demonstrated that
hepcidin, secreted from astrocytes, induced the internalization
and ubiquitination of hBMVEC Fpn when seeded in close
proximity in a model BBB system (McCarthy and Kosman,
2014b). This observation suggests that regulation of iron
release from the basolateral surface of BMVEC is due to
hepcidin secreted by neighboring glial cells, at the least.
Whether the secretion of hepcidin from astrocytes is part
of a feedback loop triggered by BMVEC-secreted iron has
yet to be definitively determined. However, Simpson et al
have recently demonstrated that basolateral BMVEC iron
efflux can be increased by astrocyte-conditioned media from
iron-depleted astrocytes. In contrast, media from iron-loaded
astrocytes decreased basolateral BMVEC iron efflux (Simpson
et al., 2015). These data are indicative of an existing
feedback loop at the BBB that is modulated by astrocyte iron
status.
Since both duodenal enterocytes and BMVEC constitute
barrier systems, and the Fpn endogenous to each is regulated
to a similar extent by hepcidin, it seems likely that they would
both express the same isoform of Fpn, which is the Fpn1b
isoform. The Rouault group performed immunohistochemistry
and western blotting experiments assaying for Fpn in the brains
of wild type (WT) and IRP2−/− mice (Wu et al., 2004). They
found no change in the relative expression of Fpn between the
wild type and the IRP2−/− mice maintained on either low or
normal iron diets suggesting that the Fpn1b isoform, which does
not respond to changes in cellular iron content (Zhang et al.,
2009), may constitute the major isoform of Fpn expressed by
the brain (Wu et al., 2004). If the Fpn1b isoform is the major
player in iron efflux from cells of the brain, then the significance
of brain hepcidin in regulating the cell surface expression of Fpn
in the brain would increase dramatically. At this point however,
it remains unclear whether BMVEC express the Fpn1a and/or the
Fpn1b isoform.
BMVEC–Astrocyte Signaling Network in
Brain Iron Trafficking
As noted above, glial cell hepcidin and sCp provide the regulatory
signals responsible for managing iron efflux from BMVEC: sCp
stimulates iron efflux by enhancing Fpn surface localization
and catalyzing iron release; hepcidin knocks down Fpn surface
localization and thereby reduces iron efflux. There is however
an additional layer of complexity in regards to the regulation
of iron transport at this cellular junction (Figure 3). That is,
cytokine signaling from BMVEC to astrocytes seems to play a
role in modulating the expression of astrocyte sCp (McCarthy
and Kosman, 2014a). Specifically, astrocyte Cp gene expression
increases in response to the signaling molecules interleukin-
1β (IL-1β) and IL-6 (di Patti et al., 2004; Conley et al., 2005;
Persichini et al., 2010; Sidhu et al., 2011; McCarthy and Kosman,
FIGURE 3 | Cell-cell signaling in brain iron uptake. Illustrated
is the signaling pathway from blood to BMVEC (A) and then
through the abluminal space (B) to astrocytes neighboring BMVEC
(C). Circulating inflammatory signals stimulate interleukin
expression and secretion from BMVEC. These cytokines stimulate
astrocyte expression and secretion of sCp into the interstitium (D).
This sCp supports an increase of iron efflux from the adjacent
BMVEC (McCarthy and Kosman, 2014a).
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2014a). BMVEC have been shown to express and secret both
IL-1β and IL-6 into their culture medium suggesting that
BMVEC could directly influence the expression of astrocyte
Cp (Podor et al., 1989; Sironi et al., 1989; Corsini et al., 1996;
Frigerio et al., 1998; Wilson et al., 2007; McCarthy and Kosman,
2014a). Until recently however, the connection between BMVEC
secretion of cytokines IL-6 and IL-1β and their induction of
neighboring astrocyte Cp gene expression had not been drawn.
Our lab has recently demonstrated that IL-1β and IL-6, secreted
from hBMVEC, directly modulate the expression of astrocyte
sCp which, in turn, acts on hBMVEC Fpn to enhance iron efflux
from the cell (McCarthy and Kosman, 2014a). Based on these
data, we suggest that hBMVEC have the capacity to modulate
their own iron efflux through this intricate signaling network
involving IL-1β and IL-6.
Interleukins such as IL-1β and IL-6 are often involved
in the inflammatory response; therefore, their expression by
hBMVEC and their subsequent downstream effect on astrocyte
sCp gene expression are likely responsive to inflammatory
signals (Figure 3). Indeed, addition of the bacterial endotoxin
lipopolysaccharide (LPS) to the apical surface of hBMVEC
increased the gene expression of both IL-1β and IL-6 and as well
as the gene expression of sCp within astrocytes seeded on the
basolateral side of the hBMVEC. However, data would indicate
that only IL-1β plays a role in modulating neighboring astrocyte
sCp gene expression in the presence of the inflammatory
signaling molecule LPS (McCarthy and Kosman, 2014a). In
addition to modulating astrocyte sCp levels, inflammatory
cytokines (tumor necrosis factor alpha, IL-6, and LPS) have
been shown to alter the expression of the iron regulatory
proteins DMT1, Fpn, and hepcidin in cells of the CNS (Urrutia
et al., 2013; Zhang et al., 2014). Regulation of these proteins
by inflammatory stimuli were not investigated in endothelial
cells.
An important question is whether the effect of LPS on
astrocyte sCp production and increased brain iron import is
a protective mechanism for the brain or if it is a mechanism
by which the bacterium can disrupt the BBB and gain access
to the brain. In regards to the first possibility, the brain may
be protected by drawing iron out of the local environment
of the blood, that is, withholding iron from the circulating
pathogen. Alternatively, the microorganism may be creating a
local environment of high oxidative stress incurred by excessive
brain iron entry, thereby disrupting the barrier formed by
the BMVEC. In this case the bacterium can readily enter the
brain via paracellular trafficking around the distressed BMVEC.
This would not be the first instance in which a pathogen
alters the expression of iron regulatory proteins to support
its proliferative capacity. The parasite Leishmania amazonesis
infects macrophages and induces an up regulation in the
macrophage hepcidin production (Ben-Othman et al., 2014).
This, in turn, causes a decrease in macrophage Fpn on the
cell surface providing more intracellular iron for the parasite
to utilize for replication (Ben-Othman et al., 2014). Further
investigation regarding the significance of BMVEC abluminal
interleukin secretion as a result of receptor activation at the
apical, blood membrane is clearly warranted.
Amyloid Precursor Protein (APP) in Brain
Iron Trafficking
There is abundant evidence for a correlation between brain
iron trafficking and protein aggregation in Alzheimer’s disease
(AD; Loef and Walach, 2012; Roberts et al., 2012; Greenough
et al., 2013; Rouault, 2013; Schröder et al., 2013; Becerril-
Ortega et al., 2014; Everett et al., 2014a,b). The underlying
molecular basis of this apparent link between brain iron and
the progression of this disease has not been delineated. The two
salient features of AD pathophysiology are Aβ-peptide plaques
and neuronal death. These indices of AD have been linked to iron
by two hypotheses: (1) an intracellular iron-induced neuronal
oxidative stress; or (2) an amyloidogenesis ‘‘catalyzed’’ by
extracellular, interstitial iron. These two mechanistic proposals
are not mutually exclusive. Indeed, some evidence suggests that
redox active iron is produced in the course of Aβ aggregation
(Everett et al., 2014a). Irrespective of the molecular details of
disease progression, the data support a role for iron in this
process.
One insight into this role follows from the question, what is
the physiologic function of amyloid precursor protein (APP)?
Certainly, this protein has not been selected for the purpose
of causing dementia in the elderly. As a recent review noted:
‘‘Despite intensive research, the normal functions of the APP
isoforms remain an enigma’’ (Nalivaeva and Turner, 2013).
That one of its functions is related to iron homeostasis is
strongly indicated by the fact that APP translation is regulated
synchronously with ferritin via a 5′ UTR that contains an iron
binding protein response element (Rogers et al., 2002, 2008).
Thus, as cell iron increases the expression of APP increases
as well. There is also evidence that indicates an increase in
Beta secretase 1 (BACE1) expression and activity towards APP
in PC12 cells treated with iron (Kim and Yoo, 2013). BACE1
is a protease involved in the extracellular cleavage of APP;
subsequent cleavage of the remaining membrane-associated APP
by γ-secretase forms (Aβ; Vassar et al., 1999). These data suggest
a model in which increases in iron in the cells in the CNS would
result in an increase in Aβ; reasonably, this alone could be the
underlying connection between iron and amyloidogenesis.
However, there is a second and likely more critical link,
one suggested by the fact that sAPP binds to Fpn (Duce et al.,
2010; McCarthy et al., 2014; Wong et al., 2014); APP may also
exhibit a similar interaction (Wong et al., 2014). The binding
site on Fpn is not known, however, the docking motif on
APP has been identified. It is found within a short sequence
at the C-terminal end of the αB helix in the protein’s E2
domain. The sequence of this peptide and its relation to the
APP molecule is shown in Figure 4; illustrated is APP695,
the most abundant splice form in the brain (Jacobsen et al.,
1991). We have designated this peptide FTP for Ferroportin
Targeting Peptide (McCarthy et al., 2014). In binding to Fpn, FTP
stabilizes it in the membrane; this stabilization is likely due to
a suppression of the hepcidin-independent retrograde recycling
of Fpn into the cytoplasm that has been observed (Ganz,
2011). More significantly, however, is the apparent antagonism
between FTP and hepcidin; this is illustrated in Figure 5. In this
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FIGURE 4 | The ferroportin binding element in the APP. (A) A
structural diagram depicting APP695, the predominant splice variant in
the brain (modified from Muller and Wild, 2013). The E2 domain is
indicated; note the first two C-terminal helices in this extracellular APP
structural element. (B) Ribbon diagram of these first two helices
(αBαC). The ferroportin binding motif is at the C-terminal end of αB;
this motif is indicated by the included side chain display. Structure is
based on PBD 3UMH. (C) Sequence of the ferroportin binding
element designated Ferroportin Targeting Peptide (McCarthy et al.,
2014).
scenario, sAPP released from either glial cells or neurons in the
neurovascular unit binds to Fpn in the basolateral membrane of
hBMVEC and suppresses the normal regulation due to glial cell
hepcidin as outlined above. This hypothesis for the connection
between iron and Aβ-dependent neurodegeneration is under
investigation.
Synopsis of Iron Transport at the BBB and
Neurological Disorders
Iron acts as a double-edged sword in living organisms. The
ability to accept and donate electrons makes iron essential to
life. Yet, when mismanaged, iron becomes highly toxic to cells;
iron-induced generation of reactive oxygen species resulting in
cell death is not uncommon (Rottkamp et al., 2001; Eaton and
Qian, 2002; Altamura and Muckenthaler, 2009; Anderson and
Wang, 2012). Neurological disorders have been attributed to
both brain iron overload (i.e., Parkinson’s disease and AD) and
brain iron deficiency (i.e., restless legs syndrome). In either
case, the mismanagement of brain iron levels may involve
the dysregulation of iron transport across the blood-brain
barrier.
While it is known that iron accumulation is associated
with both Alzheimer’s and Parkinson’s disease, the role that
the BBB plays in modulating the increased brain iron load
associated with these diseases is unclear (Gaasch et al., 2007;
Altamura and Muckenthaler, 2009; Bolognin et al., 2011). In
the case of AD, an accumulation of Aβ peptides adjacent to
the endothelial cells of the BBB (cerebral amyloid angiogenesis)
often precedes the neuron-associated Aβ peptide aggregates
(Langer et al., 2011). A recent model we have proposed suggests
that the sAPP fragment, generated during the cleavage events
forming Aβ, may stabilize Fpn on the basolateral surface of
FIGURE 5 | Iron and the progression of amyloidogenesis. As noted in the
text, the expression of APP and (some of) the metalloproteases responsible for
its cleavage into sAPP (and Aβ) is up-regulated by iron. This diagram highlights
the role that sAPP plays in regulating the flux of iron into the abluminal space.
In binding to BVMEC Fpn, sAPP potentiates the stabilization of Fpn at the
basal surface that is otherwise provided by sCp. In addition, sAPP binding to
Fpn via its ferroportin targeting peptide motif (FTP) likely antagonizes the
inhibitory action of hepcidin (Hepc). In this model, sAPP, together with a
ferroxidase (sCp), stimulates iron flux into the brain interstitium; in regards to
brain pathology, this excess iron can support either or both oxidative stress
and protein aggregation.
BMVEC. This stabilization of BMVEC Fpn may allow for
increased flux of iron into the brain. Subsequently, the iron
may become associated with the local Aβ peptide aggregates
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leading to formation of neurotoxic oligomeric Aβ species and the
progression of AD (Bolognin et al., 2011;McCarthy and Kosman,
2015).
Alternatively, it is possible that iron transport across the
BBB is detrimentally effected by the chronic neuroinflammation
that accompanies the progression of both Alzheimer’s and
Parkinson’s disease. Chronic neuroinflammation and persistent
microglia activation is a hallmark of these neurodegenerative
disorders (Cahill et al., 2009; Maezawa et al., 2011; Cherry
et al., 2014; Li et al., 2014; Morales et al., 2014). Excessive
or mismanaged brain iron exacerbates the activation state of
microglia resulting in excess production of reactive oxygen
species and neurotoxicity (Urrutia et al., 2013; Thomsen et al.,
2015). The elderly are more prone to systemic infections and
stroke both of which may further exacerbate the inflammatory
status of the brain ultimately leading to a breakdown in the
BBB allowing for uncontrolled influx of iron into the brain
parenchyma (Stankiewicz and Brass, 2009).
On the opposite end of the spectrum are patients with
restless leg syndrome (RLS) which is associated with brain iron
deficiency. Iron deficiency in these patients is hypothesized
to cause dysfunction of dopaminergic systems resulting in the
symptoms associated with the disease (Connor, 2008). Patients
with RLS have increased transferrin and decreased ferritin levels
in their cerebral spinal fluid (CSF) compared to control (Earley
et al., 2000; Mizuno et al., 2005). This change in the iron
management proteins ferritin and transferrin in the CSF could
be the result of either increased brain iron efflux; alternatively
this could be a compensatory mechanism to transport iron into
the brain across the brain-CSF barrier via transferrin- or ferritin-
mediated pathways. The role of the BBB in RLS remains to be
thoroughly investigated.
Conclusion
The studies reviewed in this article provide an overview of the
pathways that support iron transport across the BMVEC of the
BBB. While several iron handling proteins have been identified
in BMVEC in vivo, their expression and their mechanism of
action have been investigated mainly through the use of in
vitro model systems that re-create the BMVEC and astrocyte
interactions at the BBB. The mechanisms of iron regulation at
the basolateral surface of BMVEC that are detailed in this review
closely mimic those described for the duodenal barrier system.
That is, both ferroxidase and hepcidin activity seem to create a
natural balancing act regarding the control of iron efflux from
the cell system. An additional factor in this balancing is coming
into strong focus, namely APP and the protein/peptide products
of its proteolysis. The normal physiology of the APP-hepcidin
antagonism presumably maintains iron homeostasis in as much
as this part of the balancing act has been selected for. With this
perspective, the long-term pathophysiologic consequence of this
mechanism may simply be the devastating consequence of the
life-span doubling in the past 200 years.
Beyond the BBB, our lab has begun to understand the
mechanism of iron uptake into primary hippocampal neurons.
Our current understanding is that hippocampal neurons
can accumulate both non-Tf-bound and Tf-bound substrates.
Evidence suggests that Zip8 is the major ion channel for iron
uptake into hippocampal neurons (Ji and Kosman, 2015). We
hope to examine the influence of neuronal paracrine signaling
on iron efflux from the basolateral surface of BMVEC. Neurons
undoubtedly have the ability to influence the properties of the
BBB and it is reasonable to propose that this influence could
extend to regulating iron flux into the brain at the BBB. Whether
the iron provided as substrate to neurons comes directly from
BMVEC or only via astrocytes has yet to be determined; recent
experiments have indicated that astrocytes act as a buffer for
excess iron, thus preventing the over-accumulation of iron by
neurons (Pelizzoni et al., 2013). Future experiments should
investigate the role neurons play in drawing iron across the BBB
into the brain.
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